Rare Diseases, Manganelli (Asnp): "Contro Neuropathy Disimmune Developing Targeted Therapies"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
(Adnkronos) • The therapeutic panorama of dysimmune neuropathies is changing rapidly. Alongside traditional therapies, which continue to play a fundamental role, research is developing new direct treatments against increasingly specific biological targets: B lymphocytes, the FcRn receptor of immunoglobulins G (IgG) and the complement. The goal is to respond to the still unsatisfied needs, [...] L'articolo Rare Diseases, Manganelli (Asnp): •Contr…
newsbiella.it
(Adnkronos) - The therapeutic panorama of dysimmune neuropathies is changing rapidly. Alongside traditional therapies, which continue to play a fundamental role, research is developing new direct treatments...
Biotechnology is today one of the main drivers of innovation in medicine. In dysimmune neuropathies, from immunoglobulins derived from human plasma, the result of a chain that combines the value of donation with the excellence of production technologies, up to the development of new biological therapies based on innovative mechanisms of action, biotechnology has expanded the opportunities for treatment and continues to feed scientific progress.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
